Dupilumab-Associated Blepharoconjunctivitis: Clinical and Morphological Aspects

被引:1
|
作者
Serino, Federica [1 ,2 ]
Dattilo, Valeria [1 ,2 ]
Cennamo, Michela [1 ,2 ]
Roszkowska, Anna Maria [3 ]
Gola, Massimo [4 ]
Magliulo, Manfredi [4 ]
Magnaterra, Elisabetta [4 ]
Mencucci, Rita [1 ,2 ]
机构
[1] Careggi Univ Hosp, Neuromuscular & Sense Organs Dept, Eye Clin, I-50139 Florence, Italy
[2] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, I-50019 Florence, Italy
[3] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, I-98166 Messina, Italy
[4] Azienda USL Toscana Ctr, Allergol & Pediat Dermatol Unit, I-50122 Florence, Italy
关键词
Dupilumab; atopic dermatitis; meibomian glands; cornea; DRY EYE DISEASE; ATOPIC-DERMATITIS;
D O I
10.3390/biomedicines11123104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: To describe the clinical and morphologic changes in the ocular surface microstructure of patients affected with moderate-to-severe Atopic Dermatitis (AD) before and during Dupilumab treatment. Methods: This is a monocentric observational study on thirty-three patients affected with AD before and during Dupilumab treatment. All patients underwent a slit-lamp examination: complete clinical assessment, Break Up Time test (BUT), Schirmer test, and corneal staining grading (Oxford scale) were performed. Meibomian Glands Dysfunction (MGD) evaluation (Meibography), Non-invasive Keratograph Break Up Time test (NIKBUT), Tear Meniscus Height (TMH), and ocular Redness Score (RS) have been investigated using an OCULUS Keratograph. In vivo images of the conjunctiva, cornea, and meibomian glands have been acquired by confocal microscopy. Results: Sixty-six eyes were included in our study: twenty-two eyes of 11 naive patients with indication for treatment but not in therapy yet (Group 1) and forty-four eyes of 22 patients treated with Dupilumab for at least 4 months (subcutaneous administration of 300 mg every 2 weeks) (Group 2). Either patients treated with Dupilumab or naive patients with moderate-to-severe forms of AD had a tear film instability (TBUT and NIKBUT reduced), whereas the quantity of the tear film was overall normal (Schirmer test and TMH), without statistically significant differences between the two groups. When Meibography was performed with the Keratograph, the difference between Group 1 and Group 2 was statistically significant in terms of Meiboscore (p = 0.0043 and p = 0.0242, respectively), as well as the difference in terms of mean RS. These results paired well with the confocal microscopy results in which we found a decrease in the goblet cell population in the conjunctival epithelium in the treated group (5.2 cells/mm), along with inflammatory cells that were more concentrated around the adenoid lumina of the meibomian glands. Conclusions: In recent years, the use of Dupilumab has been increasing, but mild-to-severe conjunctivitis is a common side effect. Our major results demonstrate a loss of meibomian glands at the Keratograph examination: we can assume a reduced meibum secretion and an evaporative dry eye with MGD. We suggest that the inflammation of the ocular surface may involve not only the cornea and the conjunctiva, but also the meibomian glands, and Dupilumab may play a role. However, the frequency of clear conjunctivitis is not as common as reported in the literature.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases
    Kychygina, Anna
    Cassagne, Myriam
    Tauber, Marie
    Galiacy, Stephane
    Paul, Carle
    Fournie, Pierre
    Simon, Michel
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2022, 62 (03) : 519 - 533
  • [32] Dupilumab-Associated Healing of Alopecia Areata in an Atopic Dermatitis Patient
    Aszodi, Nora
    Pumnea, Teodora
    Wollenberg, Andreas
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (09) : 602 - 605
  • [33] Dupilumab-associated mycosis fungoides: a cross-sectional study
    Hamp, Austin
    Hanson, Jamie
    Schwartz, Robert A.
    Lambert, W. Clark
    Alhatem, Albert
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 315 (09) : 2561 - 2569
  • [34] Dupilumab-associated mycosis fungoides: a cross-sectional study
    Austin Hamp
    Jamie Hanson
    Robert A. Schwartz
    W. Clark Lambert
    Albert Alhatem
    Archives of Dermatological Research, 2023, 315 : 2561 - 2569
  • [35] Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases
    Anna Kychygina
    Myriam Cassagne
    Marie Tauber
    Stéphane Galiacy
    Carle Paul
    Pierre Fournié
    Michel Simon
    Clinical Reviews in Allergy & Immunology, 2022, 62 : 519 - 533
  • [36] Dupilumab-Associated Sarcoidosis: Review of a Case and Consideration of Potential Mechanisms
    Schuster, J.
    Georas, S. N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [37] Dupilumab-associated facial and neck dermatitis successfully treated with baricitinib
    Magarreiro-Silva, Antonio
    Pimenta, Rita
    Gouveia, Ana Isabel
    Mendes-Bastos, Pedro
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 (05): : 704 - 706
  • [38] Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis
    Treister, Alison D.
    Kraff-Cooper, Cheryl
    Lio, Peter A.
    JAMA DERMATOLOGY, 2018, 154 (10) : 1208 - 1211
  • [39] Dupilumab-Associated Mycosis Fungoides with a CD8+Immunophenotype
    Park, Ariel
    Wong, Lulu
    Lang, Annalise
    Kraus, Christina
    Anderson, Nancy
    Elsensohn, Ashley
    DERMATOPATHOLOGY, 2022, 9 (04): : 385 - 391
  • [40] Dupilumab-associated facial and neck dermatitis successfully treated with baricitinib
    Magarreiro-Silva, Antonio
    Pimenta, Rita
    Gouveia, Ana Isabel
    Mendes-Bastos, Pedro
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024,